Literature DB >> 18449582

Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease.

J W Baddley1, J R Perfect, R A Oster, R A Larsen, G A Pankey, H Henderson, D W Haas, C A Kauffman, R Patel, A K Zaas, P G Pappas.   

Abstract

Cryptococcus neoformans is an uncommonly recognized cause of pneumonia in HIV-negative patients. Because of its propensity to disseminate to the meninges and other sites, a lumbar puncture is recommended for patients with pulmonary cryptococcosis, regardless of other risk factors. This study explored clinical and laboratory features to help predict which patients had pulmonary disease alone versus those who had pulmonary plus extrapulmonary disease. A retrospective chart review at 15 medical centers was performed from 1990 to 2000 of all HIV-negative patients who had pulmonary cryptococcosis. Demographic, clinical, radiographic, and laboratory features were evaluated to determine factors that differentiated those patients who had extrapulmonary disease. Among 166 patients who had pulmonary cryptococcosis, 122 had pulmonary infection only and 44 had pulmonary plus extrapulmonary (disseminated) disease. A negative serum cryptococcal antigen titer was more common in patients with pulmonary disease alone (p < 0.01). Multivariate analysis demonstrated that patients who had disseminated disease were more likely than those who only had pulmonary disease to have cirrhosis (p = 0.049), headache (p < 0.001), weight loss (p = 0.003), fever (p = 0.035), altered mental status (p < 0.001), and to be receiving high-dose corticosteroids (p = 0.008). In this large cohort of HIV-negative patients with pulmonary cryptococcosis, there were easily distinguished clinical and laboratory features among patients with pulmonary disease alone versus those with pulmonary plus extrapulmonary disease. These findings may be helpful in the evaluation of HIV-negative patients with pulmonary cryptococcosis with regard to the need for lumbar puncture or to search for disseminated disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18449582     DOI: 10.1007/s10096-008-0529-z

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  30 in total

1.  Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial.

Authors:  Annemarie E Brouwer; Adul Rajanuwong; Wirongrong Chierakul; George E Griffin; Robert A Larsen; Nicholas J White; Thomas S Harrison
Journal:  Lancet       Date:  2004-05-29       Impact factor: 79.321

2.  Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.

Authors:  M S Saag; W G Powderly; G A Cloud; P Robinson; M H Grieco; P K Sharkey; S E Thompson; A M Sugar; C U Tuazon; J F Fisher
Journal:  N Engl J Med       Date:  1992-01-09       Impact factor: 91.245

3.  Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial.

Authors:  R A Larsen; M A Leal; L S Chan
Journal:  Ann Intern Med       Date:  1990-08-01       Impact factor: 25.391

4.  Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy.

Authors:  P G Pappas; J R Perfect; G A Cloud; R A Larsen; G A Pankey; D J Lancaster; H Henderson; C A Kauffman; D W Haas; M Saccente; R J Hamill; M S Holloway; R M Warren; W E Dismukes
Journal:  Clin Infect Dis       Date:  2001-07-26       Impact factor: 9.079

5.  Pulmonary cryptococcosis in patients without HIV infection.

Authors:  J A Aberg; L M Mundy; W G Powderly
Journal:  Chest       Date:  1999-03       Impact factor: 9.410

6.  Early mycological treatment failure in AIDS-associated cryptococcal meningitis.

Authors:  P A Robinson; M Bauer; M A Leal; S G Evans; P D Holtom; D A Diamond; J M Leedom; R A Larsen
Journal:  Clin Infect Dis       Date:  1999-01       Impact factor: 9.079

7.  Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks.

Authors:  W E Dismukes; G Cloud; H A Gallis; T M Kerkering; G Medoff; P C Craven; L G Kaplowitz; J F Fisher; C R Gregg; C A Bowles; S Shadomy; A M Stamm; R B Diasio; L Kaufman; S Soong; W C Blackwelder
Journal:  N Engl J Med       Date:  1987-08-06       Impact factor: 91.245

Review 8.  Cryptococcosis.

Authors:  J R Perfect
Journal:  Infect Dis Clin North Am       Date:  1989-03       Impact factor: 5.982

9.  Association between hepatitis C infection and other infectious diseases: a case for targeted screening?

Authors:  Hashem B El-Serag; Bhupinderjit Anand; Peter Richardson; Linda Rabeneck
Journal:  Am J Gastroenterol       Date:  2003-01       Impact factor: 10.864

10.  Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study.

Authors:  Françoise Dromer; Simone Mathoulin-Pélissier; Odile Launay; Olivier Lortholary
Journal:  PLoS Med       Date:  2007-02       Impact factor: 11.069

View more
  40 in total

1.  Challenges in dealing with a cirrhotic patient.

Authors:  Diana Spinelli; Sarah Damanti; Francesca Minonzio; Cinzia Hu; Maria Domenica Cappellini
Journal:  Intern Emerg Med       Date:  2012-03-15       Impact factor: 3.397

2.  Robust Th1 and Th17 immunity supports pulmonary clearance but cannot prevent systemic dissemination of highly virulent Cryptococcus neoformans H99.

Authors:  Yanmei Zhang; Fuyuan Wang; Kristin C Tompkins; Andrew McNamara; Aditya V Jain; Bethany B Moore; Galen B Toews; Gary B Huffnagle; Michal A Olszewski
Journal:  Am J Pathol       Date:  2009-11-05       Impact factor: 4.307

3.  Cryptococcus neoformans-induced macrophage lysosome damage crucially contributes to fungal virulence.

Authors:  Michael J Davis; Alison J Eastman; Yafeng Qiu; Brian Gregorka; Thomas R Kozel; John J Osterholzer; Jeffrey L Curtis; Joel A Swanson; Michal A Olszewski
Journal:  J Immunol       Date:  2015-01-30       Impact factor: 5.422

Review 4.  Innate host defenses against Cryptococcus neoformans.

Authors:  Camaron Hole; Floyd L Wormley
Journal:  J Microbiol       Date:  2016-02-27       Impact factor: 3.422

5.  Cryptococcosis and cryptococcal meningitis: New predictors and clinical outcomes at a United States academic medical centre.

Authors:  Bahar H Kashef Hamadani; Carlos Franco-Paredes; Bruce McCollister; Leland Shapiro; J David Beckham; Andrés F Henao-Martínez
Journal:  Mycoses       Date:  2018-01-23       Impact factor: 4.377

Review 6.  Advances in the diagnosis of fungal pneumonias.

Authors:  Bryan T Kelly; Kelly M Pennington; Andrew H Limper
Journal:  Expert Rev Respir Med       Date:  2020-04-21       Impact factor: 3.772

Review 7.  Approach to the Solid Organ Transplant Patient with Suspected Fungal Infection.

Authors:  Judith A Anesi; John W Baddley
Journal:  Infect Dis Clin North Am       Date:  2015-12-28       Impact factor: 5.982

Review 8.  Role of dendritic cell-pathogen interactions in the immune response to pulmonary cryptococcal infection.

Authors:  Alison J Eastman; John J Osterholzer; Michal A Olszewski
Journal:  Future Microbiol       Date:  2015       Impact factor: 3.165

9.  Risk Factors for Cryptococcal Meningitis: A Single United States Center Experience.

Authors:  Andrés F Henao-Martínez; Lilyana Gross; Bryan Mcnair; Bruce McCollister; Kristen DeSanto; Jose G Montoya; Leland Shapiro; J David Beckham
Journal:  Mycopathologia       Date:  2016-08-08       Impact factor: 2.574

10.  Susceptibility to progressive Cryptococcus neoformans pulmonary infection is regulated by loci on mouse chromosomes 1 and 9.

Authors:  Scott F Carroll; Erin I Lafferty; Adam Flaczyk; T Mary Fujiwara; Robert Homer; Kenneth Morgan; J C Loredo-Osti; Salman T Qureshi
Journal:  Infect Immun       Date:  2012-09-17       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.